We searched MEDLINE and PubMed for articles published in English between Jan 1, 1980, and March 31, 2015, with the following search terms: “Hemophilia/diagnosis[Majr] OR Hemophilia/hemorrhage[Majr] OR Hemophilia/drug therapy/therapy[Majr] OR Hemophilia [Majr] AND Antibodies[Majr]”, and “(haemophilia [TI] OR hemophilia [TI]) AND (diagnos* OR therap* OR treatmen*) AND “2015/03/30”[PDAT]”. After excluding articles on the basis of their titles or abstracts, the remaining articles and those
SeminarThe past and future of haemophilia: diagnosis, treatments, and its complications
Introduction
Haemophilia is an inherited bleeding disorder caused by deficiency or dysfunction of the coagulation proteins factor VIII, leading to haemophilia A, and factor IX, leading to haemophilia B. Since these plasma glycoproteins have an essential role in coagulation, faults cause decreased and delayed generation of thrombin, giving rise to defects in clot formation that lead to haemorrhagic diathesis. These defects are associated with bleeding episodes affecting soft tissue, joints, and muscles. Repeated haemorrhages result in chronic arthropathy, with loss of joint movement.1 At present, patients receive intravenous replacement therapy of the deficient coagulation factors, either at the time of bleeding (ie, on-demand therapy) or as a prophylactic regimen. These disorders are inherited as X-linked recessive traits—ie, male individuals are affected and female individuals are asymptomatic or mildly affected carriers. Globally, the prevalence of haemophilia A is around 1 in 5000 male births, and 1 in 30 000 male births for haemophilia B.1, 2 These figures are similar throughout the world regardless of ancestry or ethnic origin. In this Seminar, we provide an overview of the diagnosis of haemophilia and describe the clinical manifestations and treatment (both on-demand and prophylactic). Finally, we discuss inhibitor formation as a complication of replacement therapy and its treatment.
Section snippets
Diagnosis
Coagulation screening tests typically reveal a prolonged activated partial thromboplastin time with a normal prothrombin time.3 Measurement of factor VIII or IX clotting activity is used for diagnosis. On the basis of the residual coagulant activity in blood (factor VIII C or factor IX C), haemophilia is classified into three main forms: severe, moderate, and mild. Patients with a coagulation factor level of less than 1 IU/dL (ie, <1% of normal) are classified as severe and constitute about
Clinical manifestations
The clinical pictures of patients with haemophilia A and B are largely similar, and conflicting data are reported in the literature. Some evidence suggests that patients with haemophilia B have a lower bleeding frequency and better long-term outcomes than those with haemophilia A,39, 40 although a 2014 study41 suggested similar severity and variation in bleeding phenotype.
The risk of haemorrhage depends both on the severity of clotting factor deficiency and on the age of the patient. The
Treatment strategies
The main treatment is replacement therapy (also known as substitution therapy)—ie, administration of the deficient clotting factor to achieve adequate haemostasis. On-demand treatment is infusion of the deficient clotting factor at the time of bleeding. The appropriate dose, frequency, and number of concentrate infusions depend on the type and severity of the bleed. In 2013, the World Federation of Haemophilia Treatment Guidelines Working Group published detailed recommendations on disease
Development of treatment
The first treatment for haemophilia consisted of direct blood transfusion in 1840. In the 1950s and much of the 1960s, bleeding episodes were treated with fresh frozen plasma. Modern treatment started in 1965 with identification of the cryoprecipitate fraction of fresh frozen plasma by Judith Pool.68 Subsequently, technologies to separate factor VIII or IX from large pools of donor plasma resulted in freeze-dried, lyophilised factor VIII or IX concentrates,69 which made home therapy possible
Conclusion
Over the past 20 years, the diagnosis and treatment of haemophilia have improved considerably. The production of novel therapeutic proteins has been a topic of great interest to biopharmaceutical companies, and several methods have been developed to optimise and ensure the safety and effectiveness of these products. The half-life limitations of haemostatic drugs have led to the redesign of therapeutic proteins to increase their clinical potential. Although the half-lives of recombinant factor
Search strategy and selection criteria
References (141)
- et al.
How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults
Mayo Clin Proc
(2007) - et al.
Developmental hemostasis: age-specific differences in the levels of hemostatic proteins
J Thromb Haemost
(2013) - et al.
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile
J Thromb Haemost
(2010) - et al.
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
Blood
(2012) - et al.
Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe haemophilia A
Blood
(2002) - et al.
Evaluation of DHPLC in the analysis of hemophilia A
J Biochem Biophys Methods
(2001) - et al.
Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene
J Thromb Haemost
(2005) - et al.
Identification of deletion carriers in hemophilia B: quantitative real-time polymerase chain reaction or multiple ligation probe amplification
Transl Res
(2009) - et al.
A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden
Am J Hum Genet
(2013) - et al.
Hemophilia B Leyden and once mysterious cis-regulatory mutations
Trends Genet
(2014)
Hemophilia B: molecular pathogenesis and mutation analysis
J Thromb Haemost
‘Founder’ effect in different families with haemophilia B mutation
Lancet
Genetic sequence analysis of inherited bleeding diseases
Blood
Presence of foetal DNA in maternal plasma and serum
Lancet
Preimplantation genetic diagnosis
Lancet
Phenotypic heterogeneity in severe hemophilia
J Thromb Haemost
Blood-induced joint disease: the pathophysiology of haemophilic arthropathy
J Thromb Haemost
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
J Thromb Haemost
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases
Lancet
AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider
J Thromb Haemost
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
Blood
Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide
Blood
Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-man trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A
J Thromb Haemost
Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
J Thromb Haemost
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
Blood
Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX
J Thromb Haemost
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Blood
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients
Blood
Origins and mechanisms of miRNAs and siRNAs
Cell
Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
J Thromb Haemost
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
Blood
A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of hemophilia A
Mol Ther
UK Haemophilia Centre Doctors' Organisation. The incidence of FVIII and FIX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–1999
J Thromb Haemost
Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A
Blood
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A
Blood
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
J Thromb Haemost
The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A
J Thromb Haemost
The hemophilias—from royal genes to gene therapy
N Engl J Med
The increasing prevalence of haemophilia
Thromb Haemost
Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis
Thromb Haemost
Comparison of three methods for measuring factor VIII levels in plasma
Am J Clin Pathol
Monitoring haemophilia severity and treatment: new or old laboratory tests?
Haemophilia
Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype
Hamostaseologie
Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays
Thromb Haemost
Guideline on the management of haemophilia in the fetus and neonate
Br J Haematol
Standardization of FVIII & FIX assays
Haemophilia
Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A
Nat Genet
Identification of de novo deletion in the factor VIII gene by MLPA technique in two girls with isolated factor VIII deficiency
Haemophilia
Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions
Haemophilia
Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France. Description of 62 novel mutations
Thromb Haemost
Cited by (319)
Nanoparticles and siRNA: A new era in therapeutics?
2024, Pharmacological ResearchA bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state
2024, Journal of Thrombosis and HaemostasisKnowledge and attitudes toward gene therapy of a cohort of Italian patients with hemophilia
2024, Journal of Thrombosis and HaemostasisPharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis
2023, Journal of Thrombosis and Haemostasis